- Novogen (Nasdaq: NVGN) $6.84. Novogen rising sharply Thursday after the company announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status. For more color, click here.